Commentary

Video

Dr Chamie on the FDA Approval of N-803 Plus BCG for BCG-Unresponsive NMIBC

Karim Chamie, MD, discusses the FDA approval of nogapendekin alfa plus BCG for patients with BCG-unresponsive non–muscle invasive bladder cancer.

Karim Chamie, MD, associate professor, urology, the University of California, Los Angeles, discusses the significance of the FDA approval of nogapendekin alfa inbakicept-pmln (Anktiva; N-803) plus Bacillus Calmette–Guérin (BCG) for patients with BCG-unresponsive non–muscle invasive bladder cancer (NMIBC).

On April 22, 2024, the FDA approved N-803 plus BCG for the treatment of patients with BCG-unresponsive NMIBC with carcinoma in situ (CIS) with or without papillary tumors. This regulatory decision was based on findings from the phase 2/3 QUILT-3.032 trial (NCT03022825), in which a complete response (CR) rate of 62% (95% CI, 51%-73%) was observed in patients with BCG-unresponsive NMIBC who received the combination (n = 77). Notably, 58% of patients who achieved a CR experienced a duration of response (DOR) lasting at least 12 months, and 40% of patients with a CR experienced a DOR lasting 24 months or longer. Previously reported findings from cohort A of QUILT-3.032, which included patients with CIS, showed that the combination induced a CR rate of 71% (95% CI, 59.6%-80.3%) among 82 patients who had experienced disease progression on prior treatment. The median follow-up for this analysis was 23.9 months.

Commonly reported adverse effects in QUILT-3.032 included dysuria, increased creatinine, hematuria, micturition urgency, urinary frequency, urinary tract infection, musculoskeletal pain, increased potassium, pyrexia, and chills.

This FDA-approved regimen is a welcome addition to the NMIBC treatment paradigm, Chamie says. Although patients with bladder cancer face a challenging diagnosis, the current array of therapies for this disease provides patients with several effective treatment options, Chamie emphasizes. Historically, BCG-unresponsive NMIBC has been considered an end-stage disease, and patients with this disease have often needed to undergo a cystectomy, Chamie explains. However, the combination of N-803 and BCG provides these patients with an alternative to bladder removal, according to Chamie.

With this approval, N-803 joins an array of other FDA-approved treatment options for patients with NMIBC but will likely be considered the best-in-class agent, Chamie notes. Now that this agent is commercially available, many patients with BCG-unresponsive disease will seek access to this therapy, Chamie concludes.

Related Videos
John H. Strickler, MD
Brandon G. Smaglo, MD, FACP
Cedric Pobel, MD
Ruth M. O’Regan, MD
Michael R. Grunwald, MD, FACP
Peter Forsyth, MD
John N. Allan, MD
Dr Dorritie on the Clinical Implications of the 5-Year Follow-Up Data From CAPTIVATE in CLL/SLL
Minoo Battiwalla, MD, MS
Kathleen N. Moore, MD, MS